![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 11-Apr-2013[ | E-mail |
Share ] Contact: Barbara Bachtler
bachtler@mdc-berlin.de
49-309-406-3896
Helmholtz Association of German Research Centres
The plaque deposits in the brain of Alzheimer's patients are surrounded by the brain's own immune cells, the microglia. This was already recognized by Alois Alzheimer more than one hundred years ago. But until today it still remains unclear what role microglia play in Alzheimer's disease. Do they help to break down the plaque deposit? A study by researchers of the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch and Charit Universittsmedizin Berlin has now shed light on these mysterious microglia during the progression of Alzheimer's disease. (PLOS One, doi:10.1371/journal.pone.0060921)*
Dr. Grietje Krabbe of the laboratory of Professor Helmut Kettenmann (MDC) and Dr. Annett Halle of the Neuropathology Department of the Charit headed by Professor Frank Heppner demonstrated that the microglial cells around the deposits do not show the classical activation pattern in mouse models of Alzheimer's disease. On the contrary, in the course of the Alzheimer's disease they lose two of their biological functions. Both their ability to remove cell fragments or harmful structures and their directed process motility towards acute lesions are impaired. The impact of the latter loss-of-function needs further investigation. The plaques consist of protein fragments, the beta-amyloid peptides, which in Alzheimer's disease are deposited in the brain over the course of years. They are believed to be involved in destroying the nerve cells of the affected patients, resulting in an incurable cognitive decline.
However, just why the microglial cells, which cluster around the deposits, are inactivated or lose their functionality is still not fully understood. The researchers concluded that this process occurs at a very early stage of disease development and is likely triggered by the beta-amyloid. This is confirmed by the fact that the loss-of-function of the microglial cells in the mice could be reversed by beta-amyloid antibodies thereby decreasing the beta-amyloid burden. According to the researchers, the potential to restore microglial function by directed manipulation should be pursued and exploited to develop treatments for Alzheimer's disease.
###
**Functional impairment of microglia coincides with beta-amyloid deposition in mice with Alzheimer-like pathology
Grietje Krabbe1,4,*, Annett Halle2,3,*, Vitali Matyash1, Jan L Rinnenthal2, Gina D Eom2, Ulrike Bernhardt2, Kelly R Miller2, Stefan Prokop2, Helmut Kettenmann1,#, Frank L Heppner2,#
1 Max Delbrueck Center for Molecular Medicine (MDC), Robert-Roessle-Str. 10, 13125 Berlin, Germany
2 Department of Neuropathology, Charit-Universittsmedizin Berlin, Charitplatz 1, 10117 Berlin, Germany
3 Center of Advanced European Studies and Research (caesar), Ludwig-Erhard-Allee 2, 53175 Bonn, Germany
4 Present address: Gladstone Institute of Neurological Disease, 1650 Owens Street, San Francisco, CA 94158, USA
*,# These authors contributed equally to this work.
Contact:
Barbara Bachtler
Press Department
Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch
in the Helmholtz Association
Robert-Rssle-Strae 10; 13125 Berlin, Germany
Fax: +49-0-30-94-06-38-33
e-mail: presse@mdc-berlin.de
http://www.mdc-berlin.de/
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 11-Apr-2013[ | E-mail |
Share ] Contact: Barbara Bachtler
bachtler@mdc-berlin.de
49-309-406-3896
Helmholtz Association of German Research Centres
The plaque deposits in the brain of Alzheimer's patients are surrounded by the brain's own immune cells, the microglia. This was already recognized by Alois Alzheimer more than one hundred years ago. But until today it still remains unclear what role microglia play in Alzheimer's disease. Do they help to break down the plaque deposit? A study by researchers of the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch and Charit Universittsmedizin Berlin has now shed light on these mysterious microglia during the progression of Alzheimer's disease. (PLOS One, doi:10.1371/journal.pone.0060921)*
Dr. Grietje Krabbe of the laboratory of Professor Helmut Kettenmann (MDC) and Dr. Annett Halle of the Neuropathology Department of the Charit headed by Professor Frank Heppner demonstrated that the microglial cells around the deposits do not show the classical activation pattern in mouse models of Alzheimer's disease. On the contrary, in the course of the Alzheimer's disease they lose two of their biological functions. Both their ability to remove cell fragments or harmful structures and their directed process motility towards acute lesions are impaired. The impact of the latter loss-of-function needs further investigation. The plaques consist of protein fragments, the beta-amyloid peptides, which in Alzheimer's disease are deposited in the brain over the course of years. They are believed to be involved in destroying the nerve cells of the affected patients, resulting in an incurable cognitive decline.
However, just why the microglial cells, which cluster around the deposits, are inactivated or lose their functionality is still not fully understood. The researchers concluded that this process occurs at a very early stage of disease development and is likely triggered by the beta-amyloid. This is confirmed by the fact that the loss-of-function of the microglial cells in the mice could be reversed by beta-amyloid antibodies thereby decreasing the beta-amyloid burden. According to the researchers, the potential to restore microglial function by directed manipulation should be pursued and exploited to develop treatments for Alzheimer's disease.
###
**Functional impairment of microglia coincides with beta-amyloid deposition in mice with Alzheimer-like pathology
Grietje Krabbe1,4,*, Annett Halle2,3,*, Vitali Matyash1, Jan L Rinnenthal2, Gina D Eom2, Ulrike Bernhardt2, Kelly R Miller2, Stefan Prokop2, Helmut Kettenmann1,#, Frank L Heppner2,#
1 Max Delbrueck Center for Molecular Medicine (MDC), Robert-Roessle-Str. 10, 13125 Berlin, Germany
2 Department of Neuropathology, Charit-Universittsmedizin Berlin, Charitplatz 1, 10117 Berlin, Germany
3 Center of Advanced European Studies and Research (caesar), Ludwig-Erhard-Allee 2, 53175 Bonn, Germany
4 Present address: Gladstone Institute of Neurological Disease, 1650 Owens Street, San Francisco, CA 94158, USA
*,# These authors contributed equally to this work.
Contact:
Barbara Bachtler
Press Department
Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch
in the Helmholtz Association
Robert-Rssle-Strae 10; 13125 Berlin, Germany
Fax: +49-0-30-94-06-38-33
e-mail: presse@mdc-berlin.de
http://www.mdc-berlin.de/
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-04/haog-nfo041113.php
pat summit brewers matt cain adastra holocaust remembrance day chesapeake energy dick clark death
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.